Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 5 30 versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 5 30 versus TAYTULLA.
AUROVELA 1.5/30 vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin (FSH, LH) release via negative feedback on pituitary; norethindrone acetate inhibits ovulation by suppressing LH surge, altering cervical mucus and endometrial lining.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (1.5 mg norethindrone acetate, 30 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone: 8-10 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved within 5-7 days.
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal (25% norethindrone metabolites, 5% ethinyl estradiol metabolites) and fecal (60% norethindrone, 30% ethinyl estradiol); <1% unchanged drug in urine.
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive